- Home
- WETO vs CRBP Comparison
WETO vs CRBP Comparison
Compare WETO & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WETO
- CRBP
- Stock Information
- Founded
- WETO 2019
- CRBP 2009
- Country
- WETO China
- CRBP United States
- Employees
- WETO N/A
- CRBP N/A
- Industry
- WETO
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- WETO
- CRBP Health Care
- Exchange
- WETO NYSE
- CRBP Nasdaq
- Market Cap
- WETO 88.0M
- CRBP 96.5M
- IPO Year
- WETO 2025
- CRBP N/A
- Fundamental
- Price
- WETO $1.85
- CRBP $8.22
- Analyst Decision
- WETO
- CRBP Strong Buy
- Analyst Count
- WETO 0
- CRBP 10
- Target Price
- WETO N/A
- CRBP $53.56
- AVG Volume (30 Days)
- WETO 2.3M
- CRBP 214.0K
- Earning Date
- WETO 01-01-0001
- CRBP 08-05-2025
- Dividend Yield
- WETO N/A
- CRBP N/A
- EPS Growth
- WETO N/A
- CRBP N/A
- EPS
- WETO N/A
- CRBP N/A
- Revenue
- WETO $5,350,773.00
- CRBP N/A
- Revenue This Year
- WETO N/A
- CRBP N/A
- Revenue Next Year
- WETO N/A
- CRBP $150.03
- P/E Ratio
- WETO N/A
- CRBP N/A
- Revenue Growth
- WETO N/A
- CRBP N/A
- 52 Week Low
- WETO $1.50
- CRBP $4.64
- 52 Week High
- WETO $4.30
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- WETO N/A
- CRBP 54.23
- Support Level
- WETO N/A
- CRBP $7.26
- Resistance Level
- WETO N/A
- CRBP $7.90
- Average True Range (ATR)
- WETO 0.00
- CRBP 0.53
- MACD
- WETO 0.00
- CRBP -0.01
- Stochastic Oscillator
- WETO 0.00
- CRBP 78.59
About WETO WEBUS INTERNATIONAL LIMITED
Webus International Ltd operates on a business model of Mobility-as-a-Service to identify and solve inefficiencies associated with inflexible or low-quality public transportation and provide cost-efficient and customized mass transportation services under different scenarios with comprehensive digital platforms. It offers commute shuttle service, customized chartered bus service, packaged tour service and other service to customers.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.